Literature DB >> 7784051

A complex between E2F and the pRb-related protein p130 is specifically targeted by the simian virus 40 large T antigen during cell transformation.

D A Wolf1, H Hermeking, T Albert, T Herzinger, P Kind, D Eick.   

Abstract

The p130 protein is a recently cloned member of the retinoblastoma protein family. We show here that transformation of NIH3T3-L1 fibroblasts (L1 cells) by the simian virus 40 large T antigen (LTAg) depends on the disruption of DNA binding complexes between transcription factor E2F and p130. LTAg binds to the pocket region of p130 in vivo and disrupts the E2F-p130 complexes. E2F-p130 complexes are present only in quiescent L1 cells and disappear at the G1/S phase boundary concomitantly to induction of DNA synthesis and expression of the E2F-regulated cdc2 gene. p130 is a substrate of cyclin-dependent kinase 2 (Cdk2) in vitro and associates with a Cdk in vivo which is activated upon serum stimulation in late G1. Overexpression of p130 inhibits cdc2 promoter activity and entry of quiescent L1 cells into S phase. The results demonstrate that p130 is negative regulator of cell cycle progression which is specifically targeted by LTAg during cell transformation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7784051

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A.

Authors:  S Altiok; M Xu; B M Spiegelman
Journal:  Genes Dev       Date:  1997-08-01       Impact factor: 11.361

2.  Nucleocytoplasmic shuttling of p130/RBL2: novel regulatory mechanism.

Authors:  Anton Chestukhin; Larisa Litovchick; Katherine Rudich; James A DeCaprio
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

3.  c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry.

Authors:  O W Prall; E M Rogan; E A Musgrove; C K Watts; R L Sutherland
Journal:  Mol Cell Biol       Date:  1998-08       Impact factor: 4.272

4.  Differential regulation of the retinoblastoma family of proteins during cell proliferation and differentiation.

Authors:  J Garriga; A Limón; X Mayol; S G Rane; J H Albrecht; E P Reddy; V Andrés; X Graña
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

5.  p300 family members associate with the carboxyl terminus of simian virus 40 large tumor antigen.

Authors:  N L Lill; M J Tevethia; R Eckner; D M Livingston; N Modjtahedi
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

6.  Novel mechanisms of E2F induction by BK virus large-T antigen: requirement of both the pRb-binding and the J domains.

Authors:  K F Harris; J B Christensen; E H Radany; M J Imperiale
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

7.  E1A 12S and 13S of the transformation-defective adenovirus type 12 strain CS-1 inactivate proteins of the RB family, permitting transactivation of the E2F-dependent promoter.

Authors:  B M Pützer; H Rumpf; S Rega; D Brockmann; H Esche
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

8.  The human cytomegalovirus IE1-72 protein interacts with the cellular p107 protein and relieves p107-mediated transcriptional repression of an E2F-responsive promoter.

Authors:  E E Poma; T F Kowalik; L Zhu; J H Sinclair; E S Huang
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

9.  In vivo structure of the human cdc2 promoter: release of a p130-E2F-4 complex from sequences immediately upstream of the transcription initiation site coincides with induction of cdc2 expression.

Authors:  S Tommasi; G P Pfeifer
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

10.  BK virus large T antigen: interactions with the retinoblastoma family of tumor suppressor proteins and effects on cellular growth control.

Authors:  K F Harris; J B Christensen; M J Imperiale
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.